Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension

• 作者: Huai-yu Wang Suyuan Peng Zhanghui Ye Pengfei Li Qing Li Xuanyu Shi Rui Zeng Ying Yao Fan He Junhua Li Liu Liu Shuwang Ge Xianjun Ke Zhibin Zhou Gang Xu Ming-hui Zhao Haibo Wang Luxia Zhang Erdan Dong
• 来源期刊: 医学前沿
• 年，卷（期）: 2022,（1）
• 所属期刊栏目: Research Articles
• 页码范围: 102-110
• 页数: 9页
• 语种: 英文

摘要

Consecutively hospitalized patients with confirmed coronavirus disease 2019(COVID-19)in Wuhan,China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin-angiotensin system inhibitor(RAS-I)and the outcome of this disease.Associations between the use of RAS-I(angiotensin-converting enzyme inhibitor(ACEI)or angiotensin receptor blocker(ARB)),ACEI,and ARB and in-hospital mortality were analyzed using multivariate Cox proportional hazards regression models in overall and subgroup of hypertension status.A total of 2771 patients with COVID-19 were included,with moderate and severe cases accounting for 45.0％and 36.5％,respectively.A total of 195(7.0％)patients died.RAS-I(hazard ratio(HR)=0.499,95％confidence interval(CI)0.325-0.767)and ARB(HR=0.410,95％CI 0.240-0.700)use was associated with a reduced risk of all-cause mortality among patients with COVID-19.For patients with hypertension,RAS-I and ARB applications were also associated with a reduced risk of mortality with HR of 0.352(95％CI 0.162-0.764)and 0.279(95％CI 0.115-0.677),respectively.RAS-I exhibited protective effects on the survival outcome of COVID-19.ARB use was associated with a reduced risk of all-cause mortality among patients with COVID-19.